This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn  


Oxfordshire plays a pivotal role in UK’s ambition to be a scientific superpower according to a new report by Advanced Oxford

Oxfordshire plays a pivotal role in UK’s ambition to be a scientific superpower according to a new report by Advanced Oxford Business leaders and academics alike have welcomed an insightful new report and interactive dashboard published by Advanced Oxford in conjunction with Elsevier. Oxfordshire’s Innovation Engine 2023 report assesses the growth of the region’s science and technology ecosystem over the last 10 years, the challenges ahead... Read more

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting Scancell Holdings plc ("Scancell" or the "Company") Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting ModiFY trial progressing through monotherapy expansion cohorts and combination... Read more

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics... Read more

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with... Read more

OrganOx Chief Medical Officer, Professor Peter Friend, Elected as Vice President of Royal College of Surgeons of England

Oxford, United Kingdom, 12 May 2023: OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces that Chief Medical Officer, Professor Peter Friend, has been elected as Vice President of the Royal College of Surgeons of England. Professor Friend, a... Read more